Advances in Targeted Immunotherapy in Cancers, 2nd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 20 July 2024 | Viewed by 108
Special Issue Editor
Interests: tumor microenvironment; tumor immunology; tumor stem cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy is a kind of cancer treatment that boosts a person’s own immune system to fight cancer cells. It includes several types, such as such as Chimeric antigen receptor T cell therapies, cancer vaccines, non-specific immunotherapies, and so on. With the discovery of T cell immune checkpoints, such as CTLA-4 and PD-1/PD-L1, and the promising benefits of immune checkpoint inhibitor application in solid tumors, immunotherapy has revolutionized the treatment of malignant neoplasms. Immune checkpoint inhibitors induce tumor regression and long-term durable cancer control in certain percentages of advanced melanoma and non-small cell lung cancer patients.
However, only a minority of patients benefit from this anticancer therapy. Thus, it is important to understand the underlying functioning mechanism of different types of immunotherapy, and explore the sensitive/specific biomarkers or novel targets that will work synergistically with immunotherapy to boost the response and efficacy.
As Volume 1 of the Special Issue “Advances in Targeted Immunotherapy in Cancers” was successful, we reopen this Special Issue again in the International Journal of Molecular Sciences (ISSN 1422-0067, IF 5.6, JCR Category Q1). For this Special Issue, we welcome the submission of original research and review papers. Potential topics include but are not limited to the following:
- Molecular functioning mechanisms of immunotherapy;
- Sensitive and specific biomarkers of response to immunotherapy;
- Novel targets that work synergistically with immunotherapy;
- Molecular mechanisms of potential side-effects of immunotherapy.
Dr. Na Luo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- chimeric antigen receptor T cell therapies
- immune checkpoint inhibitors
- CTLA-4 and PD-1/PD-L1
- biomarkers
- novel targets
